

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3558392

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST	
CONVEYING PARTY DATA		
Name		Execution Date
TRIPLEPOINT CAPITAL LLC		09/24/2015
RECEIVING PARTY DATA		
Name:	JUVARIS BIOTHERAPEUTICS, INC.	
Street Address:	6200 STONERIDGE MALL ROAD	
City:	PLEASANTON	
State/Country:	CALIFORNIA	
Postal Code:	94588	
PROPERTY NUMBERS Total: 25		
Property Type	Number	
Patent Number:	5705655	
Patent Number:	5830878	
Patent Number:	6011148	
Patent Number:	5736395	
Patent Number:	6693086	
Patent Number:	7807822	
Patent Number:	6344446	
Patent Number:	7026468	
Patent Number:	7314746	
Patent Number:	7741300	
Application Number:	11327987	
Patent Number:	7771945	
Application Number:	12399896	
Application Number:	12411377	
Patent Number:	8044215	
Application Number:	12563012	
Application Number:	12796961	
Application Number:	12850969	
Application Number:	12919204	
Application Number:	61039381	

PATENT

Property Type	Number
Application Number:	61098005
Application Number:	61308856
PCT Number:	US1126188
PCT Number:	US0938307
PCT Number:	US1032723

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 858-587-2510

Email: docketing@wageniplaw.com

Correspondent Name: WAGENKNECHT IP LAW GROUP PC

Address Line 1: 5677 OBERLIN DRIVE

Address Line 2: SUITE 204

Address Line 4: SAN DIEGO, CALIFORNIA 92121

ATTORNEY DOCKET NUMBER:	JUVARA00GEN
NAME OF SUBMITTER:	RAMONA DERYAN
SIGNATURE:	/Ramona DeRyan/
DATE SIGNED:	10/06/2015

Total Attachments: 14

source=Juvaris_Release_SecurityInterest#page1.tif
source=Juvaris_Release_SecurityInterest#page2.tif
source=Juvaris_Release_SecurityInterest#page3.tif
source=Juvaris_Release_SecurityInterest#page4.tif
source=Juvaris_Release_SecurityInterest#page5.tif
source=Juvaris_Release_SecurityInterest#page6.tif
source=Juvaris_Release_SecurityInterest#page7.tif
source=Juvaris_Release_SecurityInterest#page8.tif
source=Juvaris_Release_SecurityInterest#page9.tif
source=Juvaris_Release_SecurityInterest#page10.tif
source=Juvaris_Release_SecurityInterest#page11.tif
source=Juvaris_Release_SecurityInterest#page12.tif
source=Juvaris_Release_SecurityInterest#page13.tif
source=Juvaris_Release_SecurityInterest#page14.tif

RELEASE OF SECURITY INTEREST

This Release of Security Interest is made as of September 24, 2015 by TRIPLEPOINT CAPITAL LLC ("Lender") in favor of JUVARIS BIOTHERAPEUTICS, INC., a Delaware corporation ("Company").

RECITAL

WHEREAS Company granted to Lender a security interest in the copyrights, patents and trademarks described on Exhibit A and attached hereto, respectively, (collectively, the "Intellectual Property") to Lender under a Plain English Intellectual Property Security Agreement dated as of September 6, 2011 (the "Security Agreement"), and recorded with the US Library of Congress Copyright Office and the US Patent and Trademark Office as set forth on Exhibits A.


WHEREAS Company has no outstanding obligations to Lender under the terms of the Security Agreement, Lender agrees to release its security interest in the Intellectual Property.

AGREEMENT

Now therefore, Lender agrees that it terminates and releases its security interest in the Intellectual Property and reassigns to Company, without warranty or recourse, all interest of Lender in the Intellectual Property.

LENDER:

TRIPLEPOINT CAPITAL LLC

By: 

Name: Sajal Srivastava

Title: President

2755 Sand Hill Road, Suite 150
Menlo Park, CA 94025
T: (650) 233-2107

EXHIBIT A



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCTOBER 5, 2011

PTAS

TED SIEN
101 CALIFORNIA STREET, SUITE 3900
WINSTON & STRAWN LLP
SAN FRANCISCO, CA 94111

501681157

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 10/04/2011

REEL/FRAME: 027015/0765
NUMBER OF PAGES: 10

BRIEF: SECURITY AGREEMENT

DOCKET NUMBER: 250121.1 (JUVARIS)

ASSIGNOR:

JUVARIS BIOTHERAPEUTICS, INC.

DOC DATE: 09/06/2011

ASSIGNEE:

TRIPLEPOINT CAPITAL LLC
2755 SAND HILL ROAD
MENLO PARK, CALIFORNIA 94025

APPLICATION NUMBER: 08247963

FILING DATE: 05/24/1994

PATENT NUMBER: 5705655

ISSUE DATE: 01/06/1998

TITLE: AMPHIPHILIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE
COMPOUNDS AND USES

APPLICATION NUMBER: 08485005

FILING DATE: 06/07/1995

PATENT NUMBER: 5830878

ISSUE DATE: 11/03/1998

TITLE: CATIONIC LIPID: DNA COMPLEXES FOR GENE TARGETING

APPLICATION NUMBER: 08691090

FILING DATE: 08/01/1996

PATENT NUMBER: 6011148

ISSUE DATE: 01/04/2000

TITLE: METHODS FOR PURIFYING NUCLEIC ACIDS

APPLICATION NUMBER: 08858571 FILING DATE: 05/19/1997
PATENT NUMBER: 5736395 ISSUE DATE: 04/07/1998
TITLE: AMPHIPHILIC IMIDAZOLINIUM DERIVATIVES

APPLICATION NUMBER: 09104759 FILING DATE: 06/25/1998
PATENT NUMBER: 6693086 ISSUE DATE: 02/17/2004
TITLE: SYSTEMIC IMMUNE ACTIVATION METHOD USING NUCLEIC ACID-LIPID COMPLEXES

APPLICATION NUMBER: 09121798 FILING DATE: 07/23/1998
PATENT NUMBER: 7807822 ISSUE DATE: 10/05/2010
TITLE: METHODS FOR PURIFYING NUCLEIC ACIDS

APPLICATION NUMBER: 09184771 FILING DATE: 11/02/1998
PATENT NUMBER: 6344446 ISSUE DATE: 02/05/2002
TITLE: CATIONIC LIPID:DNA COMPLEXES FOR GENE TARGETING

APPLICATION NUMBER: 09774284 FILING DATE: 01/29/2001
PATENT NUMBER: 7026468 ISSUE DATE: 04/11/2006
TITLE: PROCESS AND EQUIPMENT FOR PLASMID PURIFICATION

APPLICATION NUMBER: 10527618 FILING DATE: 03/11/2005
PATENT NUMBER: 7314746 ISSUE DATE: 01/01/2008
TITLE: APPARATUS AND METHOD FOR PREPARATIVE SCALE PURIFICATION OF NUCLEIC ACIDS

APPLICATION NUMBER: 11320019 FILING DATE: 12/27/2005
PATENT NUMBER: 7741300 ISSUE DATE: 06/22/2010
TITLE: METHODS OF USING NUCLEIC ACID VECTOR-LIPID COMPLEXES

APPLICATION NUMBER: 11327987 FILING DATE: 01/09/2006
PATENT NUMBER: ISSUE DATE:
TITLE: PROCESS AND EQUIPMENT FOR PLASMID PURIFICATION

APPLICATION NUMBER: 11965607 FILING DATE: 12/27/2007
PATENT NUMBER: 7771945 ISSUE DATE: 08/10/2010
TITLE: APPARATUS AND METHOD FOR PREPARATIVE SCALE PURIFICATION OF NUCLEIC ACIDS

APPLICATION NUMBER: 12399896 FILING DATE: 03/06/2009
PATENT NUMBER: ISSUE DATE:
TITLE: VACCINES USING NUCLEIC ACID-LIPID COMPLEXES

APPLICATION NUMBER: 12411377 FILING DATE: 03/25/2009
PATENT NUMBER: ISSUE DATE:
TITLE: ENHANCEMENT OF AN IMMUNE RESPONSE BY ADMINISTRATION OF A CATIONIC LIPID-DNA COMPLEX (CLDC)

APPLICATION NUMBER: 12432660 FILING DATE: 04/29/2009
PATENT NUMBER: 8044215 ISSUE DATE: 10/25/2011
TITLE: METHODS FOR THE PREPARATION OF AMPHILIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS

APPLICATION NUMBER: 12563012 FILING DATE: 09/18/2009
PATENT NUMBER: ISSUE DATE:
TITLE: VACCINE COMPOSITIONS OF M2E, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES

APPLICATION NUMBER: 12796961 FILING DATE: 06/09/2010
PATENT NUMBER: ISSUE DATE:
TITLE: METHODS FOR PURIFYING NUCLEIC ACIDS

APPLICATION NUMBER: 12850969 FILING DATE: 08/05/2010
PATENT NUMBER: ISSUE DATE:
TITLE: APPARATUS AND METHOD FOR PREPARATIVE SCALE PURIFICATION OF
NUCLEIC ACIDS

APPLICATION NUMBER: 12919304 FILING DATE: 11/23/2010
PATENT NUMBER: ISSUE DATE:
PCT NUMBER: US0901176
TITLE: USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION
OF PATHOGEN INFECTIONS

APPLICATION NUMBER: 61039381 FILING DATE: 03/25/2008
PATENT NUMBER: ISSUE DATE:
TITLE: ENHANCEMENT OF ADAPTIVE IMMUNE RESPONSE BY SYSTEMIC
ADMINISTRATION OF AN IMMUNOSTIMULANT

APPLICATION NUMBER: 61098005 FILING DATE: 09/18/2008
PATENT NUMBER: ISSUE DATE:
TITLE: VACCINE COMPOSITIONS OF M2E, HA0 AND BM2 MULTIPLE ANTIGENIC
PEPTIDES

APPLICATION NUMBER: 61308856 FILING DATE: 02/26/2010
PATENT NUMBER: ISSUE DATE:
TITLE: SUBUNIT VACCINES FOR HERPES VIRUSES AND METHODS OF USE

APPLICATION NUMBER: FILING DATE:
PATENT NUMBER: ISSUE DATE:
PCT NUMBER: US1126188
TITLE:

APPLICATION NUMBER: FILING DATE:
PATENT NUMBER: ISSUE DATE:
PCT NUMBER: US0938307
TITLE:

APPLICATION NUMBER: FILING DATE:
PATENT NUMBER: ISSUE DATE:
PCT NUMBER: US1032723
TITLE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
JUVARIS BIOTHERAPEUTICS, INC.	09/06/2011
RECEIVING PARTY DATA	
Name:	TRIPLEPOINT CAPITAL LLC
Street Address:	2755 SAND HILL ROAD
City:	MENLO PARK
State/Country:	CALIFORNIA
Postal Code:	94025
PROPERTY NUMBERS Total: 25	
Property Type	Number
Patent Number:	6693086
Patent Number:	7741300
Application Number:	12399896
Patent Number:	5705655
Patent Number:	5736395
Patent Number:	5830878
Patent Number:	6344446
Application Number:	12411377
PCT Number:	US0938307
Application Number:	61039381
Application Number:	12563012
Application Number:	61098005
Application Number:	12432660
PCT Number:	US1032723
PCT Number:	US0901176

CH \$1000.00 6693086



TRIPLEPOINT
CAPITAL

PLAIN ENGLISH INTELLECTUAL PROPERTY SECURITY AGREEMENT

This is a Plain English Intellectual Property Security Agreement dated as of September 6, 2011 by and between TriplePoint Capital LLC, a Delaware limited liability company and Juvaris Biotherapeutics, Inc., a Delaware corporation.

The words "We", "Us", or "Our", refer to the grantee, which is TriplePoint Capital LLC. The words "You" or "Your" refers to the grantor, which is Juvaris Biotherapeutics, Inc., and not any individual. The words "the Parties" refers to both TriplePoint Capital LLC and Juvaris Biotherapeutics, Inc.

The Parties have entered into a Plain English Growth Capital Loan and Security Agreement dated as of June 30, 2008, as amended by that certain Restructuring Agreement dated as of January 28, 2011 and that certain Restructuring Agreement dated as of September 6, 2011 (together with amendments, supplements, extensions and exhibits thereto, collectively the "Loan Agreement"). Pursuant to the Loan Agreement, You have granted to Us a lien on and a security interest in all the present and future rights, title, and interest that You may now have or hereafter acquire in all Patents, Trademarks, Copyrights, and applications for Patents, Trademarks and Copyrights.

In consideration for the mutual covenants and agreements contained in the Loan Agreement and this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the Parties agree as follows:

1. GRANT OF SECURITY INTEREST OF PATENTS

You grant to Us a lien upon and continuing security interest in all of Your right, title, and interest in, to and under all of the following (all of the following items of property collectively will be referred to as the "Intellectual Property Collateral"), whether now existing or hereafter arising or acquired:

- ⇒ all Patents, Patent Licenses, and Patent applications, including specifically those listed on the attached Schedule A, together with any reissues, divisions, continuations, renewals, extensions and continuations thereof;
- ⇒ all Trademarks, Trademark Licenses, and trademark applications, including specifically those listed on the attached Schedule B together with any renewals thereof;
- ⇒ all Copyrights, Copyright Licenses, and applications for Copyrights, including specifically those listed on the attached Schedule C;
- ⇒ the right to sue for past, present and future infringements of the foregoing and all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof; and
- ⇒ all Proceeds.

You represent and warrant to Us that Schedules A, B, and C attached hereto set forth any and all intellectual property rights in connection to which You have registered or filed an application with either the United States Patent and Trademark Office or the United States Copyright Office, as applicable.

2. LOAN AGREEMENT

This security interest is granted to secure the Secured Obligations, under the Loan Agreement. All the capitalized terms used but not otherwise defined are used in this Agreement with the same meaning as defined in the Loan Agreement.

IP Security Agt (Juvaris)

3. OUR RIGHT TO SUE

From and after an Event of Default, subject to the terms of the Loan Agreement, We shall have the right, but shall in no way be obligated, to bring suit in Our own name to enforce Your rights in the Intellectual Property Collateral. If We commence any such suit, You shall, at Our request, do all lawful acts and execute and deliver all proper documents or information that may be necessary or desirable to aid Us in such enforcement. You shall promptly, upon demand, reimburse and indemnify Us for all of Our costs and expenses, including reasonable attorney's fees, related to Our exercise of the above mentioned rights.

4. FURTHER ASSURANCES

You will from time to time execute, deliver and file, alone or with Us, any security agreements, or other documents to perfect and give priority to Our lien on the Intellectual Property Collateral. You will from time to time obtain any instruments or documents as We may request, and take all further action that may be reasonably necessary or desirable, or that We may reasonably request, to carry out more effectively the provisions and purposes of this Agreement or any other related agreements or to confirm, perfect, preserve and protect the liens granted to Us.

5. MODIFICATION

This Agreement can only be altered, amended or modified in a writing signed by the Parties. Notwithstanding the foregoing however, You hereby irrevocably appoint Us (and any of Our designated officers, agents or employees) as Your true and lawful attorney to modify, in Our sole discretion, this Agreement without first obtaining Your approval or signature to such modification by amending Schedules A, B, and C to this Agreement, as appropriate, to include reference to any right, title or interest in any Intellectual Property Collateral acquired by You before or after the execution hereof or to delete any reference to any right, title or interest in any Intellectual Property Collateral in which You no longer have or claim to have any right, title or interest. The appointment of Us as Your attorney in fact, and each and every one of Our rights and powers, being coupled with an interest, is irrevocable until all of the Secured Obligations have been fully repaid and performed and Our obligation to provide credit extensions to You is terminated.

6. BINDING EFFECT; REMEDIES NOT EXCLUSIVE

This Agreement shall be binding upon You and Your respective successors and assigns, and shall inure to the benefit of Us, and Our nominees and assigns.

Our rights and remedies with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Us as a matter of law or equity. Each of Our rights, powers and remedies provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Us of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Us, of any or all other rights, powers or remedies.

7. GOVERNING LAW; COUNTERPARTS


This Agreement shall be deemed made and accepted in and shall be governed by and construed in accordance with the laws of the State of California, and (where applicable) the laws of the United States of America.

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

(Signature Page to Follow)

IN WITNESS WHEREOF, You have duly executed this Agreement as of the date first set forth above.

You: JUVARIS THERAPEUTICS, INC.

Signature: 

Print Name: L. Gonzaga

Title: CFO

[SIGNATURE PAGE TO PLAIN ENGLISH INTELLECTUAL PROPERTY SECURITY AGREEMENT]

SCHEDULE A

**To Plain English Intellectual Property Security Agreement
Between Juvaris Biotherapeutics, Inc., as You (Grantor)
and TriplePoint Capital LLC, as Us (Grantee)**

PATENTS AND PATENT APPLICATIONS

PATENTS

Patent Name	Status and Date Issued	Patent Number
-------------	---------------------------	---------------

See attached.

PATENT APPLICATIONS

Name	Status & Date Filed	Application Number
------	---------------------	--------------------

See attached.

SCHEDULE B

**To Plain English Intellectual Property Security Agreement
Between Juvaris Biotherapeutics, Inc., as You (Grantor)
and TriplePoint Capital LLC, as Us (Grantee)**

TRADEMARKS AND TRADEMARK APPLICATIONS

TRADEMARKS

Name	Date Filed or Issued	Serial Number	Status
------	-------------------------	---------------	--------

None

TRADEMARK APPLICATIONS

Name	Date Filed	Serial Number	Status
------	------------	---------------	--------

None

SCHEDULE C
TO INTELLECTUAL PROPERTY SECURITY AGREEMENT
Between Juvaris Biotherapeutics, Inc., as You (Grantor)
And TriplePoint Capital LLC, as Us (Grantee)

COPYRIGHT REGISTRATIONS

Registration Number	Title	Registration Date	V&A No.
---------------------	-------	-------------------	---------

none

APPLICATIONS FOR COPYRIGHT REGISTRATIONS

Title	Date Filed	V&A No.
-------	------------	---------

none

	Title	Application No. (Filing Details)	Patent No.	Owned or Licensed by	Filing Date	Status	Expected Expiration Date**
1	Systemic Immune Activation Method Using Nucleic Acid-Lipid Complexes	US09/104,759	US6,683,686	Exclusive License - National Jewish	6/25/1998	Issued 2/17/2004	6/25/2018
2	Vaccines Using Nucleic Acid-Lipid Complexes	US11/020,019 (US Pub No. 2009/0223769)	US7,741,300	Exclusive License - National Jewish	12/27/2005	Issued 6/22/2010	6/25/2018
3	Vaccines Using Nucleic Acid-Lipid Complexes	US12/389,896 (US Pub No. 2009/0162427)		Exclusive License - National Jewish	3/5/2009	Published	6/25/2018
4	Amphiphilic Nitrogen Containing Imidazolium Derivative Compounds and Uses (DOTIM)	US08/247,963	US6,763,685	Owned by Juvenis	5/24/1994	Issued 1/6/1998	1/6/2015
5	Amphiphilic Imidazolium Derivatives (DOTIM)	US08/656,571	US6,756,388	Owned by Juvenis	5/19/1997	Issued 4/7/1998	12/17/2012
6	Amphiphilic Imidazolium Derivatives (DOTIM)	CA2176713	CA2176713	Owned by Juvenis	11/17/1994	Issued 3/22/2000	11/17/2014
7	Amphiphilic Imidazolium Derivatives (DOTIM)	515155/1995	JP2918693	Owned by Juvenis	11/17/1994	Issued 4/23/1999	11/17/2014
8	Amphiphilic Imidazolium Derivatives (DOTIM)	EP95901947.2	EP0730404B1	Owned by Juvenis	11/17/1994	Issued 2/4/2004	11/17/2014
9			Belgium EP0730404B1 BE				11/17/2014
10			Switzerland EP0730404B1 CH				11/17/2014
11			Germany EP0730404B1 DE / DE69433332-0				11/17/2014
12			France EP0730404B1 FR				11/17/2014
13			UK EP0730404B1 GB				11/17/2014
14			Ireland EP0730404B1 IE				11/17/2014
15	Cationic Lipid:DNA Complexes for Gene Targeting (DOTIM Formulations)	US08/485,006	US6,836,876	Owned by Juvenis	6/7/1995	Issued 11/3/1998	11/3/2015
16	Cationic Lipid:DNA Complexes for Gene Targeting (DOTIM)	US08/184771	US6,344,446	Owned by Juvenis	11/2/1998	Issued 2/5/2002	12/17/2012
17	Cationic Lipid:DNA Complexes for Gene Targeting (DOTIM)	AU199600061609	AU696316B1	Owned by Juvenis	6/7/1995	Issued 10/29/1998	6/7/2016
18	Cationic Lipid:DNA Complexes for Gene Targeting (DOTIM)	EP88010212.8	EP832278B1	Owned by Juvenis	6/7/1996	Issued 10/27/2004	6/7/2016
19			Belgium EP832278B1 BE				6/7/2016
20			France EP832278B1 FR				6/7/2016
21			Germany EP832278B1 DE / DE89633726-8				6/7/2016
22			UK EP832278B1 GB				6/7/2016
23			Ireland EP832278B1 IE				6/7/2016
24			Switzerland EP832278B1 CH				6/7/2016
25	Enhancement of an Immune Response by Administration of a Cationic lipid-DNA Complex (CLDC)	US12/411,377 (US Pub No. 2009/0263423)		Owned by Juvenis. Partially funded by NIH	3/25/2009	Pending	3/25/2028
26	Enhancement of an Immune Response by Administration of a Cationic lipid-DNA Complex (CLDC)	PCT US2009/038307			3/25/2009	Published	
27	Enhancement of an Immune Response by Administration of a Cationic lipid-DNA Complex (CLDC)	US61/039,381 EP 08724379.4	Europe		3/25/2009	Published	
28	Enhancement of an Immune Response by Administration of a Cationic lipid-DNA Complex (CLDC)	US61/039,381 P10910395-9	BR (PCT US2009/038307) Brazil		3/25/2009	Published	
29	Enhancement of an Immune Response by Administration of a Cationic lipid-DNA Complex (CLDC)	US61/039,381 WO2009/120811	CA (PCT US2009/038307) Canada		3/25/2009	Published	
30	Enhancement of an Immune Response by Administration of a Cationic lipid-DNA Complex (CLDC)	JP WO2009/120811	JP (PCT US2009/038307) Japan		3/25/2009	Pending	
31	Vaccine Compositions of M2e, HA0 and BM2 Multiple Antigenic Peptides	US12/563,012 (US61/098,005)		Owned by Juvenis; Partially funded by NIH	9/18/2009	Pending	9/18/2029
32	Methods for the Preparation of Amphiphilic Nitrogen Containing Imidazolium Derivative Compounds	US12/432,666		Owned by Juvenis	4/29/2009	Pending	4/29/2029
33	Methods for the Preparation of Amphiphilic Nitrogen Containing Imidazolium Derivative Compounds	PCT US2010/032723		Owned by Juvenis	4/8/2010	Pending	

	Title	Application No. (Filing Details)	Patent No.	Owned or Licensed by	Filing Date	Status	Expected Expiration Date**
34	Use of Immunogenic Compositions for the Treatment or Prevention of Pathogen Infections	PCT US09/001176		Co-Owned IP with NIAID	2/24/2010	Published	
35	Subunit Vaccines for Herpes Viruses and Methods of Use	US 61/308,656		Co-Owned IP with UPenn	2/26/2010	Provisional	
36	Subunit Vaccines for Herpes Viruses and Methods of Use	US 61/308,656	(PCT US2011/026198) Europe		2/25/2011	Provisional	
37	Methods for Purifying Nucleic Acids	US06/691090	US8,011,148	Non-Exclusive License - Valentis/Ungen	6/1/1996	Issued 1/4/2000	6/1/2016
38	Methods for Purifying Nucleic Acids	US09/121,796 (US Pub. No. 2002/0198372A1)	US 7,887,822	Non-Exclusive License - Valentis/Ungen	7/23/1996	Issued 10/6/2010	6/1/2016
39	Methods for Purifying Nucleic Acids	US12/786,961 (claims priority to US06/121,796)			6/9/2010	Unpublished	
40	Process and Equipment for Plasmid Purification (Claims to TMAE)	US09/774,284 (US Pub. No. 2001/0034435)	US7,026,468	Non-Exclusive License - Valentis/Ungen	1/29/2001	Issued 4/11/2006	7/3/2017+ 222 days
41	Process and Equipment for Plasmid Purification (Claims to HIC)	US11/327,987 (US Pub. No. 2006/0106208A1)		Non-Exclusive License - Valentis/Ungen	1/9/2006	Pending Published	7/3/2017
42	Apparatus and Method for Preparative Scale Purification of Nucleic Acids	US10/527,518 (US Pub. No. 2006- 166331A1)	US7,314,746	Non-Exclusive License - Valentis/Ungen	3/11/2005	Issued 1/1/2008	9/12/2023+ 99 days
43	Apparatus and Method for Preparative Scale Purification of Nucleic Acids	US11/985,807 (US Pub. No. 2008/0102519)	US 7,771,846	Non-Exclusive License - Valentis/Ungen	12/27/2007	Issued 8/10/2010	9/12/2023
44	Apparatus and Method for Preparative Scale Purification of Nucleic Acids	US12/650,969 (claims priority to US10/527,518)		Non-Exclusive License - Valentis/Ungen	8/5/2010	Unpublished	